Protein Kinase Inhibitors: all 15,766 studies that test it

Page 153 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• A Study of LY317615 in Patients With Brain TumorsCompletedNCT00190723Phase 2
• A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based TherapyCompletedNCT00189358Phase 2
• Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney TransplantCompletedNCT00188955Phase 4
• Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLCCompletedNCT00188617Phase 2
• Everolimus for Treating Pediatric Patients With Recurrent or Refractory TumorsCompletedNCT00187174Phase 1
• Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00185835Phase 1
• Study of Xeloda and Gleevec in Patients With Advanced Solid TumorsCompletedNCT00183833Phase 1
• Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian CancerCompletedNCT00181688Phase 2
• Pharmacokinetics of Curcumin in Healthy VolunteersCompletedNCT00181662Not applicable
• Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and NeckStatus unknownNCT00180921Phase 2
• Glivec Phase II Pediatric StudyTerminatedNCT00180830Phase 2
• Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic CarcinomaCompletedNCT00177242Phase 2
• Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast CancerCompletedNCT00174434Phase 1
• MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung CancerTerminatedNCT00174369Phase 2
• PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC PatientsCompletedNCT00174356Phase 1
• Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung CancerCompletedNCT00173875Phase 2
• Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00171977Phase 4
• Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)TerminatedNCT00171938Phase 2
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
• Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)CompletedNCT00171899Phase 4
• A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic SyndromeTerminatedNCT00171860Phase 2
• Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced CancerCompletedNCT00171587Phase 1/2
• Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsCompletedNCT00170885Phase 4
• Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant RecipientsCompletedNCT00170859Phase 4
• Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant PatientsCompletedNCT00170833Phase 3
• Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free RegimenCompletedNCT00170820Phase 4
• Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.CompletedNCT00170794Phase 3
• Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no SteroidsCompletedNCT00170053Phase 1
• Rollover Study Of Lapatinib In Cancer PatientsCompletedNCT00169533Phase 1
• Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract CarcinomasTerminatedNCT00169221Phase 2
• Study Evaluating Sirolimus in Kidney Transplant Recipients.CompletedNCT00167947Phase 3
• Sirolimus Blood Concentrations on Conversion From Oral Solution to TabletsStatus unknownNCT00166842Phase 4
• The Effect of Sirolimus on the Pharmacokinetics of TacrolimusStatus unknownNCT00166829Phase 4
• The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant PatientsStatus unknownNCT00166816Phase 4
• An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With CapecitabineTerminatedNCT00165880Phase 2
• An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and OxaliplatinCompletedNCT00165867Phase 2
• Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal CancerCompletedNCT00165854Phase 2
• A Study of E7070 in Patients With Gastric CancerTerminatedNCT00165594Phase 1/2
• Protein Tyrosine Kinases (PTK) in Multiple MyelomaCompletedNCT00165347Phase 2
• Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease SurvivorsCompletedNCT00165308Not applicable
• A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's DiseaseCompletedNCT00164749Phase 1/2
• A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT00162318Phase 1
• Study of Dasatinib in Patients With Advanced Solid TumorsTerminatedNCT00162214Phase 1
• UDCA for Symptomatic Gallstone DiseaseCompletedNCT00161083Phase 4
• Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.CompletedNCT00160043Phase 2
• Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.WithdrawnNCT00159016Phase 2
• Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer PatientsCompletedNCT00158782Phase 1
• Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLCCompletedNCT00156286Phase 2
• Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
• Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00154349Phase 2
• A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.CompletedNCT00154336Phase 2
• The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)CompletedNCT00152178Phase 3
• Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)CompletedNCT00150202Phase 3
• Efficacy and Safety of Imatinib in ChordomaCompletedNCT00150072Phase 2
• Efficacy and Safety of Everolimus in de Novo Heart Transplant RecipientsCompletedNCT00150046Phase 3
• Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.Status unknownNCT00149136Phase 2
• Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone TherapyCompletedNCT00148772Phase 2
• MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.TerminatedNCT00147550Phase 1/2
• A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced CancerTerminatedNCT00147485Phase 1
• AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One YearStatus unknownNCT00146913Phase 2
• Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell TransplantationCompletedNCT00146614Phase 2
• Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid CarcinomaCompletedNCT00144976Not applicable
• Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00144859Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
• Efficacy and Safety of Sirolimus in Combination With TacrolimusStatus unknownNCT00141804Phase 3
• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic FunctionCompletedNCT00139620Phase 1
• Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00138632Phase 1/2
• Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated MesotheliomaCompletedNCT00137826Phase 2
• Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer PatientsCompletedNCT00137800Phase 2
• Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic CancerCompletedNCT00137761Phase 2
• Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant RecipientsTerminatedNCT00137345Phase 3
• A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
• A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT00136409Phase 2
• Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT00135005Phase 1
• Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) PatientsStatus unknownNCT00134758Phase 2/3
• A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid ArthritisCompletedNCT00134693Phase 2
• Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)TerminatedNCT00134667Phase 4
• Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate CancerCompletedNCT00134355Phase 2
• Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00134069Phase 1
• TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant RecipientsCompletedNCT00133887Phase 3
• Study of Unrelated Cord Blood Transplantation Using Tacrolimus and SirolimusCompletedNCT00133367Phase 2
• Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00131989Phase 1
• Gleevec Idiopathic Pulmonary Fibrosis (IPF) StudyCompletedNCT00131274Phase 2/3
• Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2
• Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)CompletedNCT00130195Phase 2
• Study of XL820 in Adults With Solid TumorsCompletedNCT00129571Phase 1
• Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00128700Phase 1/2
• Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or MetastaticCompletedNCT00127829Phase 1
• Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid LeukemiaTerminatedNCT00126893Phase 1
• Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00126620Phase 1
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
• Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the BreastStatus unknownNCT00126464Not applicable
• Tarceva and Capecitabine for Pancreatic CancerCompletedNCT00125021Phase 2
• Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT00124280Phase 2
• Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal CancerCompletedNCT00123851Phase 2
• Imatinib in Dermatofibrosarcoma Protuberans (DFSP)CompletedNCT00122473Phase 1/2
• AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)CompletedNCT00122343Phase 2
• A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic MelanomaCompletedNCT00121680Phase 1
• A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerCompletedNCT00121628Phase 2

← Protein Kinase Inhibitors overview